Modified lysine decarboxylase enzymes
The invention provides CadA polypeptides with mutations that increase activity in alkaline pH compared to the wild-type lysine decarboxylase. The invention also provides methods of generating such mutant polypeptides, microorganisms genetically modified to overexpress the mutant polypeptides, and methods of generating such microorganism.
1. A product, which is one of the following products I) through VI):
I) a CadA variant polypeptide comprising at least one amino acid substitution at a glutamic acid residue at one or more positions selected from the group consisting of positions 291, 344, 355, 463, 482, and 499 as determined with reference to SEQ ID NO:2, wherein the glutamic acid residue occurs at the surface of the protein with the side chain oriented towards the external environment in a segment of the protein that lacks a defined secondary structure; and wherein the CadA variant polypeptide has at least 80% identity to any one of SEQ ID NOS:2 to 5;
II) a polynucleotide comprising a nucleic acid sequence encoding a CadA variant polypeptide of I);
III) an expression vector comprising a polynucleotide of II);
IV) a genetically modified host cell comprising a CadA variant polypeptide of I);
V) a genetically modified host cell comprising a polynucleotide of II), wherein the nucleic acid sequence encoding the CadA variant polypeptide is integrated into the host cell chromosome;
VI) a genetically modified host cell comprising an expression vector of III).
2. A product of claim 1 , which is I) the CadA variant polypeptide, wherein the substitution is at glutamic acid residue at one or more positions selected from the group consisting of positions 291, 344, 355, 463, 482, and 499.
3. The product of claim 1 , wherein the amino acid substitution is E291A/C/D/H/R/V/G/K/N/S, E355C/F/H/K/L/MN/P/Q/R/S/T/V/Y, or E482C/F/I/L/S/W/Y/A/H/K/M.
4. The product of claim 3 , where the amino acid substitution is E291A/C/D/H/R/V, E355C/F/H/K/L/M/N/P/Q/R/S/T/V/Y, or E482C/F/I/L/S/W/Y.
5. A product of claim 1 , which is I) the CadA variant polypeptide, wherein the CadA variant polypeptide at least 85%, at least 90%, or at least 95% identity to SEQ ID NO:2.
6. A product of claim 1 , which is I) the CadA variant polypeptide, wherein the CadA variant polypeptide has at least 80%, at least 85%, at least 90%, or at least 95% identity to SEQ ID NO:3, SEQ ID NO:4, or SEQ ID NO:5.
7. A product of claim 1 , which is I) the CadA variant polypeptide, wherein the CadA variant polypeptide is a conservatively modified variant polypeptide.
8. A product of claim 1 , which is IV) the genetically modified host cell, wherein the host cell is genetically modified to over express one or more lysine biosynthesis polypeptides.
9. A product of claim 1 , which is IV) the genetically modified host cell, wherein the host cell is a bacterium.
10. The product of claim 8 , wherein the host cell is from the genus Escherichia, Hafnia , or Corynebacteria.
11. The product of claim 8 , wherein the host cell is selected from the group consisting of Escherichia coli, Hafnia alvei and Corynebacterium glutamicum.
12. A product of claim 1 , which is VI) the genetically modified host cell, wherein the host cell is a bacterium.
13. A product of claim 1 , which is VI) the genetically modified host cell, wherein the host cell is form the genus Escherichia, Hafnia , or Corynebacteria.
14. A product of claim 1 , which is VI) the genetically modified host cell, wherein the host cell is selected from the group consisting of Escherichia coli, Hafnia alvei and Corynebacterium glutamicum.
15. A product of claim 1 , which is V) the genetically modified host cell, wherein the host cell is a bacterium.
16. The product of claim 14 , wherein the host cell is form the genus Escherichia, Hafnia , or Corynebacteria.
17. The product of claim 14 , wherein the host cell is selected from the group consisting of Escherichia coli, Hafnia alvei and Corynebacterium glutamicum.
18. A method, which is one of the following methods I) through III):
I) a method of producing cadaverine, the method comprising culturing a genetically modified host cell of claim 1 IV) under conditions in which the CadA variant polypeptide is expressed;
II) a method of producing cadaverine, the method comprising culturing a genetically modified host cell of claim 1 V) under conditions in which the CadA variant polypeptide is expressed;
III) a method of producing cadaverine, the method comprising culturing a genetically modified host cell of claim 1 VI) under conditions in which the CadA variant polypeptide is expressed.